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AbsTrACT
Preservatives continue to be in widespread use in 
ophthalmic medications due to the convenience they 
provide, regulatory requirements and the higher cost 
of alternatives. Benzalkonium chloride (BAK) remains 
the most commonly used preservative but there is a 
trend towards the use of preservative-free (PF) drops for 
glaucoma, although at a higher price. An extensive body 
of literature explores BAK toxicity on ocular structures 
in animal and laboratory studies (in vitro and in vivo). 
Non-randomised controlled studies have provided some 
supporting evidence of its toxicity in patients, especially 
in those with pre-existing ocular surface disease (OSD) 
or on multiple medications. However, there have been 
very few randomised controlled trials  that compare the 
same medication with and without BAK preservative. 
Several of these trials have never been published in any 
peer reviewed journals. Notwithstanding, those that 
have been published, have not demonstrated any clear 
benefits of the BAK-free formulations. Short duration 
and exclusion of those with OSD are limitations of these 
studies. There is a lack of evidence of clinically significant 
harm from a small number of BAK preserved drops in 
patients without OSD. This means that generally more 
expensive PF glaucoma medications should only be 
recommended for those on poly pharmacy or those with 
OSD but are not necessarily required for all patients.
InTroduCTIon
The use of preservatives extends the shelf-life of 
medications considerably. Patients would be able to 
administer their drops in a convenient and cost-ef-
fective way by allowing one large bottle of drops 
to last for a whole month. Their use has been a 
requirement in multidose containers by many regu-
latory authorities since the 1970s.1 Benzalkonium 
chloride (BAK) has been used in ophthalmology 
since the 1940s. It is by far the most common 
preservative, found in approximately 70% of eye 
drops.2 3 It is used in different concentrations varied 
from 0.004% to 0.02%. It is a quaternary ammo-
nium compound that acts as a detergent, lysing 
cell membranes and thus killing microorganisms. 
It is highly effective as a preservative. It was also 
initially thought that the detergent effect of BAK 
might be necessary for the penetration of the active 
ingredient.4
other preservatives and available alternatives
Concern over the toxicity of BAK has led to other 
classes of preservatives being developed (table 1). 
These include polyquaternium-1 (Polyquad) which 
is a detergent, the oxidising preservatives such 
as Stabilised Oxychloro Complex (SOC, trade 
name Purite) and Sodium perborate (GenAqua) 
and the ionic buffered preservative SofZia. Addi-
tionally, advances in bottle design have created 
new dispensing mechanisms (such as COMOD or 
ABAK) that allow longer lasting preservative-free 
(PF) bottles. However, these are not widely avail-
able. Furthermore, there is a trend towards unit-
dose preparations of glaucoma drops to eliminate 
the need for preservatives.5 Common preserved and 
PF glaucoma medications (drops) currently avail-
able in the UK are summarised in tables 2 and 3.
search strategy
A ‘PubMed’ search was performed using the 
terms ‘glaucoma medication’ and ‘preservative’. 
Randomised double-blind controlled clinical trials 
were sought within the results, of which only three 
comparing the same medication with and without 
preservative were selected. Other studies of interest 
are also discussed. We searched ‘glaucoma’ and 
‘preservative’ terms on ‘ ClinicalTrial. gov’ website 
in order to identify unpublished clinical trials.
Preservative toxicity
The laboratory and animal studies on the negative 
effects of BAK on the ocular structures have been 
the driving force against preservatives. Most of the 
literature concentrates on BAK as this is regarded 
as the most toxic and is the most commonly used. 
Other preservatives have been shown to exhibit 
less toxicity.6 7 In general, the antimicrobial activity 
of the preservative is inversely proportional to its 
compatibility with the ocular surface.6 Excipients 
(pharmacologically inactive substances acting as 
carriers for the active components), free radicals 
load and pH may also have an impact on the ocular 
surface. These parameter levels were found to be 
considerably variable between different glaucoma 
medications.8
bAK toxicity
BAK has been demonstrated to have detrimental 
effects on many ocular structures including the 
conjunctival tissue and corneal epithelium as well 
as the trabecular meshwork and lens epithelium.9 10
Conjunctiva
Guenoun et al and several other studies found 
that at very low doses BAK induced proapoptotic 
effects on conjunctival epithelial cell lines.11–14 
Notably though these studies did not demonstrate 
apoptotic effects from the active pressure-low-
ering compounds. In human subjects, prolonged 
exposure to multiple preserved glaucoma medica-
tions have been shown to produce inflammatory 
changes in the subepithelial conjunctiva, although 
reversible on cessation of the medication. However, 
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Table 1  Commonly used preservatives in eye drops
Compound Class Antimicrobial action Trade name Example
BAK Quaternary ammonium Detergent action dissolves cell walls and membranes N/A Lumigan, Xalatan, etc
Polyquartenium 1 Detergent Acts on cell membranes Polyquad Tears Naturale II
SOC Oxidising Oxidation of intracellular lipids and glutathione Purite Alphagan P
Sodium perborate Oxidising Forms hydrogen peroxide, oxidising action similar to the above GenAqua Genteal
Borate, sorbitol, propylene 
glycol and zinc
Ionic buffer Multiple SofZia Travatan Z
BAK, benzalkonium chloride; SOC, Stabilised Oxychloro Complex.
Table 2   Common glaucoma preparations available in preserved formulation
Preserved drops 
Medication brand name drug concentration Preservative
Preservative 
concentration
Prostaglandin analogues
  Latanoprost Xalatan 50 µg/mL Benzalkonium chloride 0.02%
  Bimatoprost Lumigan 100 and 300 µg/mL Benzalkonium chloride 0.02%
  Travoprost Travatan 40 µg/mL Polyquad 0.01%
Beta blockers
  Timolol Timolol and Timolol LA 2.5 and 5 mg/mL, Benzalkonium chloride 0.01%
  Levobunolol Betagan 5 mg/mL Benzalkonium chloride 0.004%
  Betaxolol Betoptic 2.5 and 5 mg/mL Benzalkonium chloride 0.01%
Alpha blockers
  Brimonidine Alphagan 2 mg/mL Benzalkonium chloride 0.005%
  Apraclonidine Iopidine 5 and 10 mg/mL Benzalkonium chloride, 
propylene glycol
0.01%
Carbonic anhydrase inhibitors
  Brinzolamide Azopt 10 mg/mL Benzalkonium chloride, 
disodium edetate
0.01%
  Dorzolamide Trusopt 20 mg/mL Benzalkonium chloride 0.0075%
Combinations
  latanoprost 50 µg/mL, timolol 5 mg/mL Xalacom Benzalkonium chloride 0.02%
  Lumigan 300 µg/mL, timolol 5 mg/mL Ganfort Benzalkonium chloride 0.05%
  Travatan 40 µg, timolol 5 mg/mL DuoTrav Polyquad 0.01%
  Brinzolamide 10 mg/mL, timolol 5 mg/mL Azarga Benzalkonium chloride 0.1%
  Dorzolamide 20 mg/mL, timolol 5 mg/mL Cosopt Benzalkonium chloride 0.0075%
  Brimonidine 2 mg/mL, Timolol 5 mg/mL Combigan Benzalkonium chloride 0.05%
  Brimonidine tartrate 2 mg/mL, Brinzolamide 10 mg/mL Simbrinza Benzalkonium chloride 0.03%
Source: British National Formulary 2017.
comparisons have not been made with patients on PF medica-
tions.15 16 Leal et al17 examined the histology of patients with 
hyperaemia from bimatoprost (BAK 0.005%). They concluded 
that it was not associated with inflammation, although this was 
after only 15–30 days use.
Cornea
Cell lines of three-dimensional corneal cells have shown similar 
apoptotic response to BAK, more so in superficial layers but in 
the deeper layers as well when apoptotic marker assays were 
used.18 However, other studies using the same three-dimensional 
model did not find any loss of cell viability.19 This highlights the 
difficulty of replicating studies using such models. In an animal 
model using in-vitro confocal microscopy, Liang found inflam-
matory infiltrates in the corneal epithelium, cellular swelling and 
desquamation from glaucoma medications, worst in those with 
BAK as a preservative.10
Trabecular meshwork
BAK is clearly toxic to trabecular meshwork cells. The laboratory 
studies have shown reduced cell numbers, growth and altered 
morphology20–22 and increased proapoptotic activity.23 An accu-
mulation of BAK has been found in the trabecular meshwork 
of patients treated chronically (5–10 years) with BAK preserved 
medications.24 This has led to the hypothesis, yet unproven 
though, that chronic BAK exposure might worsen glaucoma.1
Lens and other structures
BAK has been shown to strongly induce the expression of 
inflammatory mediators in lens epithelial cells25 compared with 
latanoprost or timolol. The Blue Mountains Eye Study and 
Ocular Hypertension Treatment Study both suggested higher 
rates of cataract formation in those on antiglaucoma therapy.26 27 
Miyake28 conducted studies that suggested that BAK preserved 
drops prior to cataract surgery increased the risk of cystoid 
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Table 3   Common glaucoma preparations available in non-
preserved formulation
non-preserved 
name of medication brand name drug concentration
Prostaglandin analogues
  Latanoprost Monopost 0.005%
  Bimatoprost Lumigan UD 0.03%
  Tafluprost Saflutan 0.015%
Beta blockers
  Timolol Tiopex and Timoptol unit 
dose
0.1%, 0.25% and 0.5%
Carbonic anhydrase 
inhibitors
  Dorzolamide Trusopt preservative free 2%
Combinations
  Bimatoprost/timolol Ganfort UD 0.03%, 0.5%
  Tafluprost/timolol Taptiqom 0.015% ,0.5%
  Dorzolamide/timolol Cosopt preservative free 2%, 0.5%
Source: British National Formulary 2017.
Table 4 Ocular adverse effects of preserved vs PF medications in RCTs
AEs
sheddon day Goldberg
PF bAK PF bAK PF bAK
Overall % Not reported Not reported Not reported Not reported 33.1 33.7
Conjunctival hyperaemia Not reported Not reported 23.9 26.1 21.2 19.5
Mild Not reported Not reported 17.6 21 16.5 15.6
Moderate Not reported Not reported 6.3 4.4 4.0 3.9
Severe Not reported Not reported 0 0.7 0.7 0
Pruritus Not reported Not reported 4.0 4.1 4.3 1.8
Skin pigmentation Not reported Not reported Not reported Not reported 4 1.4
Dry eye Not reported Not reported 1.7 3.1 3.2 1.1
Punctate keratitis 16.8 23.8 3.0 3.1 2.9 2.5
Eye pain Not reported Not reported Not reported Not reported 2.5 1.8
Foreign body sensation Not reported Not reported 2.3 0.7 2.2 2.1
Eye irritation 16 21.5 Not reported Not reported 2.2 1.8
Eyelash growth Not reported Not reported Not reported Not reported 1.4 2.8
Erythema Not reported Not reported Not reported Not reported 1.1 2.5
Discontinuation due to ocular AE (by patients) 4 3 2 3 4 9
AEs, adverse events; BAK, benzalkonium chloride; PF, preservative-free; RCT, randomised controlled trials.
macular oedema. At a molecular level, DNA damage has been 
noted from BAK exposure in a dose-dependent fashion.29
Clinical studies
Clinically, the detergent properties of BAK can affect the lipid 
layer of the tear film, reducing tear breakup time (TBUT) and 
goblet cell numbers and mucin production are affected as 
well.30 31 Many clinical studies have illustrated an increased level 
of corneal staining, reduced TBUT and other markers of ocular 
surface disease (OSD) with BAK preserved medications.32–34 
OSD, to quote Batra et al,35 is an ‘umbrella term that includes 
dry eye, lid disease, conjunctivitis and keratitis’. While there are 
validated scoring systems for OSD such as the Ocular Surface 
Disease Index (OSDI),36 many studies used different subjective 
measures to evaluate the frequency and severity of OSD.
A French survey of over 4000 patients found those on PF drops 
had roughly half the symptoms and signs of OSD compared with 
those using preserved drops.33 Additionally, they demonstrated 
a large reduction of symptoms and signs on reducing the dose of 
preservatives or switching to PF. However, other clinical studies 
have found little or no corneal toxicity from various concen-
trations of BAK. A meta-analysis concluded that no significant 
difference in corneal staining occurred in patients that had twice 
the dose of BAK per day as others. Furthermore, BAK containing 
drops did not produce significant corneal toxicity in the vast 
majority of patients.37
Published randomised controlled trials
Overall studies that suggest more frequent adverse effects 
on those individuals who are on preserved medications have 
not been double masked38 or have not compared the same 
preserved and non-preserved medications.39 40 There have 
been a very few double masked randomised controlled clinical 
trials (RCTs) published which PF drops are directly compared 
with the same drop containing preservative. An analysis of bias 
using the Cochrane review process was done and the following 
three RCTs were assessed as low risk. Briefly the randomisation 
processes were described, the two different medications in each 
study were dispensed in identical bottles and the investigators 
and patients were masked as to the study medication. Outcome 
data short and longer term was close to complete for all patients 
with 96%–98% of patients completing the studies with results 
reported.
These studies are summarised in table 4.
Shedden et al reported in a double-masked study of 261 
patients who were randomised 1:1  to either a PF combination 
of dorzolamide/timolol or one containing BAK at 0.0075% 
concentration.41 All patients had either ocular hypertension 
(OHT) or primary open-angle glaucoma (POAG). Efficacy was 
assessed by intraocular pressure (IOP) measurements done after 
a 3-week lead in on timolol alone and then at 2, 6 and 12 weeks 
after treatment with either PF or preserved dorzolamide/timolol 
combination. Tolerability was assessed by reported adverse 
events (AEs) by patients and objective clinical assessment. The 
efficacy of both preparations of dorzolamide/timolol was found 
to be equivalent at all time points. Overall both formulations 
were well tolerated. No statistical difference was found in terms 
of AEs between the two formulations. Furthermore, a similar 
percentage in each group had punctate epithelial erosions  on 
examination (23.8% preserved vs 16.8% PF). Three patients 
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Table 5  unpublished data from https://clinicaltrials.gov website
Comparison
(ClinicalTrial.gov identifier) Year
duration
(months) number of patients study type results
Travoprost (sofZia) vs Latanoprost BAK
(NCT00798759)
2008 3 215 Double masked RCT OSDI score slightly better with SofZia
TBUT the same
Travoprost (sofZia) vs Latanoprost BAK
(NCT00690794)
2008 3 726 Double masked RCT OSDI change similar
Absence of corneal staining similar 
(37 sofZia, 40 BAK)
Travoprost (sofZia) vs Latanoprost BAK
(NCT00527592)
2007 Not stated 54 (comparison made 
between eyes)
Double masked RCT Comfort after dose equal
BAK, benzalkonium chloride; OSDI, Ocular SurfaceDisease Index; RCT, randomised controlled trials; TBUT, tear breakup time.
in the BAK group and four in the PF group discontinued their 
medication due to adverse effects.
Day et al in a double-masked randomised clinical trial, 
compared bimatoprost 0.03% PF with bimatoprost 0.03% 
containing BAK at a concentration of 0.005%.42 They 
randomised just under 600 patients with OHT and various types 
of glaucoma. Those on other chronic ocular medication or with 
ocular surface findings were excluded, although hyperaemia 
was the only such finding which was specified. The duration of 
treatment was 12 weeks with evaluations at baseline, 2, 6 and 
12 weeks. There was no statistically or clinically significant 
difference between the two formulations in terms of tolerability. 
Ocular AEs occurred in 32% of the PF group (two of whom 
stopped treatment) and 35% of the BAK group (three of whom 
stopped). Hyperaemia rate, pruritus and punctate keratitis were 
almost identical, although more severe staining was slightly more 
common in the BAK group at 6.8% vs 3.7% (p=0.086). Foreign 
body sensation occurred more in the PF group (seven patients, 
2.3%) than in the BAK group, (two patients, 0.7%). The efficacy 
of medications was similar in both groups.
Goldberg et al compared bimatoprost 0.03%/timolol 0.5% PF 
with BAK (0.005%) preserved formulation.43 Five hundred and 
sixty-one patients with either OHT or POAG were randomised. 
Those with chronic use of other ocular medication or with 
ocular surface findings (only hyperaemia or irritation were 
mentioned) were excluded. This was a double-masked RCT 
which was conducted for 12 weeks following a washout period 
of 4–28 days (depending on their medication). Safety was eval-
uated by self-reported adverse effects, slit lamp examination 
and grading of conjunctival hyperaemia based on the Oxford 
hyperaemia scoring system. Both formulations were safe and 
well tolerated. Treatment-related AEs (table 4) were reported in 
28.8% in the PF group and 28.7% in the BAK group. Conjunc-
tival hyperaemia was the most common AE which was usually 
mild. No significant difference was found between the two 
groups in terms of conjunctival hyperaemia, pruritus, dry eye, 
eye pain, eye lash growth and eyelid erythema. Skin hyperpig-
mentation was significantly more common in those on the PF 
formulation (4% vs 1.1%, p=0.028), a finding that was thought 
to be incidental.
Efficacy
In all three aforementioned studies, the IOP lowering effect 
of the PF medications was non-inferior to the preserved 
preparation, indicating that BAK is not required for adequate 
drug penetration, in line with other studies demonstrating 
equivalent efficacy between BAK preserved and PF glaucoma 
medications.44
unpublished randomised controlled trials
Several moderately sized RCT have been carried out comparing 
BAK preserved medications to those with alternative preserva-
tives. Unpublished studies with reported results available are 
summarised in table 5.
However, no statistical analysis of the results had been 
attempted. It is not clear why these studies were not formally 
published. It could be speculated that it may have been due to 
the lack of clinically significant difference found between the 
medications being compared.
Patient satisfaction
Ultimately, glaucoma treatment can only be successful, if it is 
used by patients, thus compliance is a significant issue. Treat-
ment satisfaction has been identified as an important factor to 
improve compliance45. 
Rouland et al38 randomised over 400 patients to either 
preserved or PF latanoprost in an investigator-masked study. 
After 12 weeks, hyperaemia was worse in the preserved group 
as was the total objective ocular symptom score. However, there 
was no difference in the other objective signs (such as corneal 
staining). Furthermore, tolerance was reported as satisfactory or 
very satisfactory in more than 97% of patients in both groups. 
A survey of over 2500 patients in New Zealand45 reported high 
levels of satisfaction that was associated with the frequency of 
drops, convenience and ease of use. The presence of side effects 
was not predictive of the level of satisfaction. The only side effect 
which was significantly greater than control group (not on medi-
cation) was hyperaemia. A recent survey by Lemij et al found a 
high treatment satisfaction rate among patients despite the pres-
ence of OSD signs,46 though hyperaemia and ocular discomfort 
were the factors associated with dissatisfaction.
Preservatives in established osd
In patients with established OSD, switching to PF medications 
have been shown to be beneficial to improve their symptoms, 
signs and tolerability. Uusitalo et al39 in a study of those with 
pre-existing signs or symptoms of OSD found that symptoms 
after switching to tafluprost PF were reduced to one-third of 
baseline of latanoprost BAK preserved and signs were reduced 
by half. This study was limited by its open label nature and 
comparison of different prostaglandin analogues (rather than 
the same type of medication). In a randomised, double-masked, 
prospective study, Katz et al40 found that switching to travoprost 
PF from preserved latanoprost in those with some OSD (mild or 
worse) also led to some symptom relief in those with mild OSD 
and in the subgroup with prior preserved drop use of more than 
24 months. The corneal staining between the two groups was 
similar after 12 weeks. Interestingly there was more eye pain, 
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Table 6  Cost of 1-month supply of medication in the UK
Medication PF Preserved Premium, %
Bimatoprost 0.03% £13.75 £10.30 34
Bimatoprost/Timolol £17.94 £14.16 27
Latanoprost £8.49 £1.43 (generic) 493
Dorzolamide/Timolol £28.59 £1.65 (generic) 1633
PF, preservative-free.
irritation and hyperaemia in the PF group noted. Janulevičienė 
et al34 measured tear film osmolarity before and after switching 
from BAK preserved latanoprost to tafluprost PF in patients with 
pre-existing OSD. They found significant improvement in tear 
film osmolarity as well as TBUT and corneal staining.
Batra et al35 reported on patients with severe OSD and 
inadequately controlled glaucoma. They demonstrated that 
controlling the OSD resulted in improvement in OSD and IOP 
control. Measures used included lid hygiene, topical lubricants, 
oral doxycycline and switching to PF medications.
Skalicky et al47 found that the use of more than three glau-
coma medications was an independent predictor of adverse 
OSDI score.
Causes of variability between laboratory and clinical studies
The severity of BAK toxicity in laboratory studies and the vari-
ability in the effect found in clinical studies may partly be due to 
the extended duration of exposure in many of the in-vitro and 
in-vivo studies. In fact, clinically the concentration of BAK in the 
tear film diminishes very rapidly.48
Chemical binding reduces the amount of free BAK. Addi-
tionally, the antioxidant effect of prostaglandin analogues may 
explain the relatively high tolerance of such medications in 
the longer term.11 A study of conjunctival goblet cell density 
(CGCD)49 found that tafluprost PF and preserved latanoprost 
both caused increased CGCD at 1 month. There was a sustained 
increase of CGCD in the tafluprost group at 6 months. This was 
not reversed by switching to preserved latanoprost. However, 
those treated with the latanoprost vehicle alone had a significant 
decrease. TBUT and Schirmer tests were very similar between 
two groups. The PF group had a lower OSDI score but were not 
masked to their treatment (a possible source of bias). Different 
prostaglandin analogues may also differ in their protective 
properties.7
There is some evidence to suggest BAK exposure may reduce 
corneal sensitivity and thus symptoms.50 Furthermore, the effect 
of tear film osmolality in increasing BAK concentration may also 
explain why patients with pre-existing OSD/dry eye are more at 
risk.51
bAK effect on glaucoma surgical success
Trabeculectomy
A small number of studies have examined the effect of prior 
medical treatment on trabeculectomy success and even fewer 
have tried to look at the effect of BAK in particular. Broadway et 
al52 explored the outcome of 124 trabeculectomies. They found 
that a higher rate of failure was associated with long-term usage 
of multiple medications (all preserved, including miotics and 
sympathomimetics that are seldom used nowadays) and corre-
sponding subclinical inflammatory changes in the conjunctiva. 
Boimer and Birt53 in a retrospective study examined the results 
of 128 trabeculectomies. They compared BAK exposure using 
the number of BAK containing drops as a proxy and the dose 
corrected BAK exposure per day (adjusting for varying concen-
trations of BAK in different drops). Those with a higher number 
of preoperative drops and a higher dose corrected exposure had 
a higher risk of early trabeculectomy failure. It was not possible 
to calculate the cumulative dose of BAK received in each patient. 
However, another study of 215 trabeculectomies54 did not find 
an association between the number of medications used or length 
of usage and trabeculectomy failure. Another study explored 
tear cytokines55 demonstrated elevated levels of an inflamma-
tory mediator (monocyte chemoattractant protein-1 (MCP-1)) in 
patients taking glaucoma medications. Higher levels of MCP-1 
were found with longer duration of medication use (mostly BAK 
preserved). Additionally, a greater risk of requiring post trabe-
culectomy intervention due to higher MCP-1 level was noted. 
However, there was no association between the number of medi-
cations and the higher risk.
PF prostaglandin analogues have been found to induce 
ocular adnexa macrophage infiltration, which may be partially 
explained by excipients in the medications.56 Other common 
adverse effects of prostaglandin analogues such as orbitopathy57 
are not attributed to their preservatives. A recent Japanese study 
found better IOP control post-trabeculectomy in those patients 
who did not exhibit signs of orbitopathy due to preoperative 
prostaglandin analogues.58
Broadway reported that withdrawing medications 4 weeks 
prior to trabeculectomy surgery and administering low potency 
topical steroids (fluorometholone) reduced conjunctival inflam-
mation.59 Breusegem reported the successful use of preoperative 
anti-inflammatory medications (steroids and to a lesser extent 
non-steroidal anti-inflammatories) to improve failure rates of 
trabeculectomy surgery.60
Glaucoma aqueous shunt surgery and MIGS (minimally invasive 
glaucoma surgery)
No studies have examined the effects of prior glaucoma medi-
cations or preservative use on the success rate of tube surgery or 
MIGS procedures.
Cost issues
In general, PF preparations cost much more than the equivalent 
with preservative (table 6) (British National Formulary 2017).61 
The premium charged by the manufacturers for the PF glaucoma 
medications range from 27% to over 1600%, compared with the 
same medications with preservatives.
From a cost effectiveness perspective, studies have linked 
patient satisfaction and fewer medication changes with lower 
costs.62 However, there have not been any studies directly 
comparing the cost effectiveness of preserved versus PF 
medications.
Other preservatives
While there are no clinical studies comparing non- BAK preserved 
drops to PF drops, there have been comparisons between non- 
BAK preserved and BAK preserved.
Gandolfi et al63 randomised 371 patients to receive either 
BAK or polyquad preserved travoprost. At 3 months, adverse 
effects were generally mild and very similar in both groups.
Peace et al64 compared travoprost 0.03% with polyquad to 
BAK preserved travoprost 0.04% and found no difference 
in adverse effects (a slight increase in hyperaemia in the BAK 
preparation group may have been related to the higher travo-
prost concentration). More recently Jayanthi et al65 published a 
comparison of BAK preserved travoprost with SofZia preserved. 
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They reported significantly lower OSDI scores in patients on the 
SofZia preserved formulation. However, this study was open-la-
belled which may have caused some bias.
ConCLusIon/CLInICAL IMPLICATIons
Clearly topical medications, preservatives and the excipients and 
buffers can cause some ocular surface changes. Laboratory and 
non-level one evidence demonstrate additional adverse effects 
from BAK. There are no data available to demonstrate that the 
efficacy of glaucoma medications is reduced in the absence of 
BAK. There is also no evidence from double-masked RCTs that 
BAK causes significant OSD over and above the glaucoma medi-
cation alone in patients with a healthy ocular surface.
For those on polypharmacy or with OSD, the resultant cumu-
latively higher dose or concentration of BAK in the tear film may 
mean that preservative-free preparations are desirable in patients 
taking more than three medications or in those with pre-existing 
OSD. Symptoms and signs of toxicity should be screened for 
those on preserved drops, as there is some evidence suggesting 
that switching to PF drops will improve these.
There is no conclusive evidence that BAK per se jeopardises 
the success rate of glaucoma filtration surgery. For those who are 
likely to have glaucoma filtration surgery, minimising exposure 
to both topical agents and preservatives may be recommended. 
Whether this should be in the form of earlier surgery or a preop-
erative washout period remains to be elucidated. This is an area 
in which further research is required, particularly in light of less 
invasive surgical options emergence.
Current evidence is inadequate due to exclusion of patients 
with pre-existing OSD and the short duration of many other 
studies. Longer-term double-masked clinical trials comparing 
patients on PF drops versus preserved drops would be desirable. 
These may not be practical due to the high cost of such studies.
As clinicians dealing with ageing populations and ever-in-
creasing number of glaucoma patients, we should be conscious 
of the cost repercussions of each treatment options. Based on 
current evidence there is no justification for routine use of PF 
medication in those without significant OSD and especially 
those requiring only few medications (1–2) per day.
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